New radioactive therapy targets Hard-to-Treat breast cancer
NCT ID NCT07081555
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 30 times
Summary
This early-stage trial tests a new radioactive drug called [177Lu]Lu-ABY-271 in people with HER2-positive metastatic breast cancer that has spread and cannot be removed by surgery. The main goals are to check safety and see where the drug travels in the body. About 21 participants will receive the drug to help determine if it can be developed further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akademiska Sjukhuset
RECRUITINGUppsala, SE-751 85, Sweden
-
Karolinska University Hospital
RECRUITINGStockholm, SE-17164, Sweden
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, S-413 45, Sweden
Conditions
Explore the condition pages connected to this study.